Literature DB >> 21925308

Cancer: beyond speciation.

Mark D Vincent1.   

Abstract

A good account of the nature of cancer should provide not only a description of its consistent features, but also how they arise, how they are maintained, why conventional chemotherapy succeeds, and fails, and where to look for better targets. Cancer was once regarded as enigmatic and inexplicable; more recently, the "mutation theory," based on random alterations in a relatively small set of proto-oncogenes and tumor suppressor genes, has enjoyed widespread acceptance. The "mutation theory," however, is noticeable for its failure to explain the basis of differential chemosensitivity, for providing a paucity of targets, especially druggable ones, and for justifying the development of targeted therapies with, in general, disappointingly abbreviated clinical benefit. Furthermore, this theory has mistakenly predicted a widespread commonality of consistent genetic abnormalities across the range of cancers, whereas the opposite, that is, roiling macrogenomic instability, is generally the rule. In contrast, concerning what actually is consistent, that is, the suite of metabolic derangements common to virtually all, especially aggressive, cancers, the "Mutation Theory" has nothing to say. Other hypotheses merit serious consideration "aneuploidy theories" posit whole-genome instability and imbalance as causally responsible for the propagation of the tumor. Another approach, that is, "derepression atavism," suggests cancer results from the release of an ancient survival program, characterized by the emergence of remarkably primitive features such as unicellularity, fermentation, and immortality; existential goals are served by heuristic genomic instability coupled with host-to-tumor biomass interconversion, mediated by the Warburg effect, a major component of the program. Carcinogenesis is here seen as a process of de-speciation; however, genomic nonrestabilization raises issues as to where on the tree of life cancers belong, as a genuinely alternative modus vivendi. Philosophical considerations aside, genomic instability offers the prospect of subtle new therapies based on loss of information rather than gain; and the consistent, specific, and broad-spectrum perfidy of the Warburg effect highlights a supplemental target of the highest priority.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21925308     DOI: 10.1016/B978-0-12-387688-1.00010-7

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  33 in total

1.  The shock of being united and symphiliosis. Another lesson from plants?

Authors:  Yuri Lazebnik
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

2.  Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model.

Authors:  Charles H Lineweaver; Paul C W Davies; Mark D Vincent
Journal:  Bioessays       Date:  2014-07-14       Impact factor: 4.345

Review 3.  The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis.

Authors:  Xiaomin Lou; Ju Zhang; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2014-05-05       Impact factor: 4.534

4.  Study on attractors during organism evolution.

Authors:  Andrzej Kasperski; Renata Kasperska
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

5.  Karyotypic evolutions of cancer species in rats during the long latent periods after injection of nitrosourea.

Authors:  Mathew Bloomfield; Amanda McCormack; Daniele Mandrioli; Christian Fiala; C Marcelo Aldaz; Peter Duesberg
Journal:  Mol Cytogenet       Date:  2014-12-16       Impact factor: 2.009

Review 6.  Protecting the normal in order to better kill the cancer.

Authors:  Bingya Liu; Lewis Ezeogu; Lucas Zellmer; Baofa Yu; Ningzhi Xu; Dezhong Joshua Liao
Journal:  Cancer Med       Date:  2015-07-14       Impact factor: 4.452

7.  Cancer karyotypes: survival of the fittest.

Authors:  Joshua M Nicholson; Daniela Cimini
Journal:  Front Oncol       Date:  2013-06-07       Impact factor: 6.244

8.  Immortality of cancers: a consequence of inherent karyotypic variations and selections for autonomy.

Authors:  Peter Duesberg; Amanda McCormack
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

9.  Individual karyotypes at the origins of cervical carcinomas.

Authors:  Amanda McCormack; Jiang Lan Fan; Max Duesberg; Mathew Bloomfield; Christian Fiala; Peter Duesberg
Journal:  Mol Cytogenet       Date:  2013-10-17       Impact factor: 2.009

Review 10.  Cancer as a metabolic disease: implications for novel therapeutics.

Authors:  Thomas N Seyfried; Roberto E Flores; Angela M Poff; Dominic P D'Agostino
Journal:  Carcinogenesis       Date:  2013-12-16       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.